How to access Mepsevii from Oman, the named-patient import pathway, 2026

*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-13.

An Omani patient with mucopolysaccharidosis VII (MPS VII, Sly syndrome) may receive a prescription for Mepsevii (vestronidase alfa-vjbk) from their treating metabolic geneticist. Mepsevii is FDA-approved in the United States and manufactured by Ultragenyx Pharmaceutical. It is a recombinant beta-glucuronidase enzyme replacement therapy administered by intravenous infusion. Local availability of Mepsevii in Oman can be inconsistent: the drug may not be on every specialty pharmacy's standing formulary, the specific indication may not match what is locally registered, or the strength required may be back-ordered. When that happens, a named-patient import pathway through DGPADC remains a legitimate route for the patient whose physician has already prescribed the drug.

This guide explains the pathway, the documentation your physician needs, typical costs and indicative timing, and where Reserve Meds fits in.

The clinical situation

Mepsevii is a recombinant beta-glucuronidase enzyme replacement therapy. Mechanism: a recombinant form of human beta-glucuronidase that catalyses the hydrolysis of terminal glucuronic acid residues from glycosaminoglycans. Dosing: 4 mg/kg by intravenous infusion every two weeks, with pre-infusion antihistamine and antipyretic premedication, per FDA labeling. Baseline workup per FDA labeling includes urinary GAG baseline, cardiac and pulmonary evaluation, airway assessment, hepatosplenomegaly assessment, and infusion-reaction risk screening. The FDA boxed warning covers anaphylaxis. Other important warnings include anaphylaxis and severe allergic reactions, infusion-associated reactions, and patients with significant skeletal or airway disease may be at higher risk. Your specialist will discuss the risk-benefit profile and schedule monitoring before initiating therapy.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Is Mepsevii legally importable into Oman?

Yes, through the Directorate General of Pharmaceutical Affairs and Drug Control (DGPADC) named-patient and personal-use import framework, coordinated with the treating facility's pharmacy. Oman has an established pathway for specialty medicines approved by reference authorities (US FDA, EMA, MHRA) but not stocked or registered for the specific indication locally.

The DGPADC named-patient route allows an Oman-licensed physician to request import of a medicine when: (a) the medicine is approved by a recognised reference authority, (b) no clinically equivalent locally registered alternative is suitable for the patient's indication and history, (c) the treating physician takes clinical responsibility for use, and (d) chain of custody is documented from the US source to the administering facility. Applications are typically filed through the dispensing institution's import pharmacy on the physician's behalf, with approval issued on a per-patient, per-cycle quantity basis.

How the pathway works, step by step

1. Consultation with your treating specialist. The prescribing decision is clinical. Your specialist documents the indication, prior therapies where relevant, and rationale for Mepsevii.
2. Baseline screening. Urinary GAG baseline, cardiac and pulmonary evaluation, airway assessment, hepatosplenomegaly assessment, and infusion-reaction risk screening are confirmed and documented.
3. DGPADC named-patient application. Your specialist or the facility's import pharmacy files the application with clinical rationale, patient reference, product strength, quantity requested, and chain-of-custody plan.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from Ultragenyx Pharmaceutical's authorised distribution under DSCSA chain-of-custody.
5. Cold-chain shipment. Mepsevii requires refrigerated transport at 2 to 8 degrees Celsius. Shipments include temperature-monitored packaging with continuous loggers and tamper-evident seals.
6. Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription, and your specialist initiates therapy.

What documentation your physician needs

Your physician will typically need to provide:

• A clinical rationale letter confirming diagnosis, prior therapies where relevant, and Mepsevii as the indicated next step
• Verification of their Oman medical licence
• A patient identifier, anonymised reference where privacy is preferred
• Documented pre-treatment screening consistent with FDA labeling (see above)
• The planned dosing regimen (4 mg/kg by intravenous infusion every two weeks, with pre-infusion antihistamine and antipyretic premedication, per FDA labeling)
• A monitoring plan covering GAG baselines, airway and skeletal imaging summary, and pre-medication protocol

Reserve Meds provides a physician documentation kit tailored for MPS enzyme replacement therapy therapies, including the templates DGPADC reviewers commonly request.

Typical costs and indicative timing

Reserve Meds gives you a drug-only reference range plus a transparent delivered quote at intake. As an illustrative composite case, the US cash-pay reference range for a typical month of every-2-week infusions (weight-dependent) of Mepsevii sits in an indicative 2026 band of approximately USD 60,000 to 85,000. International logistics, DGPADC documentation handling, cold-chain shipping, and concierge coordination add incremental cost. The delivered quote we issue at intake shows each line separately.

Indicative timing for first dose after cohort intake opens is approximately 4 to 8 weeks from the moment a complete application is submitted, assuming the documentation package is clean on first pass. Refills ship on a rolling cadence aligned to the dosing schedule.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Mepsevii specifically, we provide:

• Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody from manufacturer to export.
• Documentation. Regulatory package tailored for your physician and for DGPADC review, including MPS enzyme replacement therapy class templates.
• Cold-chain logistics. Temperature-monitored, internationally tracked shipment to your named dispensing facility with continuous temperature loggers.
• Concierge case lead. A named point of contact for your family and your physician across the full case arc.

We are a coordinator. We are not the prescriber, not a pharmacy, and not a dispensing facility. All clinical decisions remain with your treating specialist, and dispensing sits with the licensed Oman pharmacy of record. Reserve Meds operates on cash-pay only and does not bill insurance.

Frequently asked

Is this legal in Oman? Yes, when executed through the DGPADC named-patient and personal-use framework with appropriate documentation, clinical rationale, and a licensed dispensing facility. The pathway is routinely used across oncology, rare disease, and immunology at Oman tertiary centers.

What about the boxed warning? The FDA boxed warning on Mepsevii covers anaphylaxis. Your specialist performs the risk-benefit assessment, schedules monitoring, and counsels the patient per labeling. Reserve Meds does not make that clinical judgement, your physician does.

Will my private health insurance cover this? Cash-pay is the default posture. Some Oman private insurers and CCHI-aligned plans reimburse named-patient imports on a case-by-case basis when the documentation package is strong. We supply documentation for your submission but do not process insurance claims.

How does cold-chain affect timing? Mepsevii ships refrigerated. We use validated packaging with continuous temperature monitoring, and arrival temperature data is logged on every shipment.

What if my physician has not filed a named-patient request before? Named-patient import is an institutional process most major Oman tertiary centers (The Royal Hospital Muscat, Sultan Qaboos University Hospital (SQUH), Khoula Hospital, Armed Forces Hospital, and Muscat Private Hospital) have encountered. Our documentation kit is written for first-time applicants and tracks what DGPADC reviewers commonly ask for.

Next step

For Mepsevii coordination in Oman, start your case at the portal or message us on WhatsApp. Our concierge case lead will respond within 24 hours.

---

Composite case examples. This content is for general information and does not constitute medical advice.